Seeking Alpha

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF), ...
Nasdaq

Can-Fite BioPharma Initiates Phase II Clinical Study for Piclidenoson in Patients with Lowe Syndrome

Can-Fite BioPharma Ltd. has announced the completion of a Phase II study design and is preparing to initiate a clinical study for Piclidenoson, a novel treatment for Lowe Syndrome, a rare genetic ...
Hosted on MSN

NCBS study links lipid imbalance to brain disorder in Lowe Syndrome patients

BENGALURU: Researchers at the National Centre for Biological Sciences (NCBS), Bengaluru, have identified how abnormal levels of specific lipids in the brain lead to neurological defects in patients ...
Hosted on MSN

NCBS develops model system to help Lowe Syndrome patients

BENGALURU: A team of researchers from the National Centre for Biological Sciences (NCBS), Bengaluru, shared details of the development of a model system which helps in designing personalised ...
Nasdaq

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that ...